Clene Inc. (NASDAQ: CLNN) priced a $7 million underwritten registered direct offering of 1,000,000 shares of common stock at $7.00 per share, with the transaction expected to close on or about May 6 2026.
The company will use the proceeds, together with its existing cash, to fund the preparation and filing of a New Drug Application for its lead candidate CNM‑Au8, support expanded access protocols, continue Phase 3 confirmatory trials, expand manufacturing capacity, and support additional early‑stage research and development activities.
Clene reported a net loss of $26.2 million for the year ended December 31 2025 and held $5.2 million in cash and cash equivalents, giving the company a current ratio of 0.83. The issuance of 1,000,000 new shares will dilute existing shareholders and is intended to extend the company’s cash runway into the fourth quarter of 2026.
Management emphasized the strategic importance of the funding: “We are committed to working with the Agency on this filing and are conducting the Phase 3 confirmatory study for CNM‑Au8, which we intend to commence in the first quarter of 2027.” “We followed the FDA’s roadmap — and the data delivered. This is a remarkably consistent dataset that makes a strong case for accelerated approval.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.